Ophthalmic Bevacizumab Reaches Critical Review Stage In EU
The sponsor of what could become the EU’s first approved ophthalmic formulation of bevacizumab needs to address outstanding issues raised by the European Medicines Agency about its filing.
You may also be interested in...
Ophthalmic Bevacizumab Sponsor Braces For High-Stakes EMA Meeting
The sponsor of an ophthalmic formulation of bevacizumab is set to speak up for its marketing authorization application during a European Medicines Agency oral explanation meeting.
Henlius Doses First Patient In China For Ophthalmic Bevacizumab
Chinese firms Shanghai Henlius Biotech and Essex Bio-Technology have announced a key milestone in their Chinese Phase I clinical study for the HLX04-O biosimilar bevacizumab candidate to treat wet age-related macular degeneration.
First Ophthalmic Formulation Of Bevacizumab Among New Filings At EMA
Using the cancer drug off-label to treat wet AMD has been controversial.